May 28, 2008 - Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced that it has entered into an option to acquire an exclusive worldwide license to issued and pending patent applications related to additional uses of oral flupirtine for the treatment of a range of ophthalmic, diabetes and diabetes-related therapeutic indications...
...The potential therapeutic indications covered by the additional intellectual property estate include glaucoma, age-related macular degeneration (AMD), retinitis pigmentosa (RP), diabetic maculopathy, and diabetic retinopathy and are supported by promising existing human clinical data generated in European countries where flupirtine has been commercially available for over 20 years and used by an estimated 1.5 million patients. The intellectual property is supported by promising multi-year clinical experience of oral flupirtine in over 100 patients with diabetic retinopathy, maculopathy, retinitis pigmentosa and glaucoma... Pipex Pharmaceuticals' Press Release -
